Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter

IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

See all formats and pricing
More options …
Volume 57, Issue 10


Trueness assessment of HbA1c routine assays: are processed EQA materials up to the job?

Vincent Delatour / Noémie Clouet-Foraison
  • Laboratoire National de Métrologie et d’Essais (LNE), Paris, France
  • University Hospital of Reims, Laboratory of Biochemistry, Reims, France
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Stéphane Jaisson / Patricia Kaiser / Philippe Gillery
Published Online: 2019-05-14 | DOI: https://doi.org/10.1515/cclm-2019-0219



With the worldwide increase of diabetes mellitus prevalence, ensuring that HbA1c assays are accurate is essential. External quality assessment (EQA) programs enable laboratories to verify that analytical methods perform according to the manufacturers’ specifications. However, assessing trueness requires commutable materials, a property that is rarely characterized for EQA materials.


The difference in bias approach was used to assess commutability of 26 processed quality control materials for 17 of the most frequently used HbA1c assays. Involved assays included immuno-assays, enzymatic assays, affinity, ion-exchange HPLC boronate affinity HPLC and capillary electrophoresis. The measurements were performed at manufacturers or expert laboratories. Assay trueness was additionally assessed against the IFCC reference measurement procedure using fresh clinical specimens that were distributed to 450 medical laboratories.


Commutability of processed EQA materials was highly heterogeneous and globally insufficient to rigorously assess the trueness of HbA1c assays. Using fresh clinical specimens, mean bias was −0.13 mmol/mol for low HbA1c (34 mmol/mol), between +1.0 and +1.3 mmol/mol for intermediate HbA1c (49 and 58 mmol/mol) and +1.2 mmol/mol for elevated HbA1c (90 mmol/mol).


This study demonstrates that due to insufficient commutability, most processed EQA materials are unsuitable to assess trueness of HbA1c assays and agreement between the different assays. These materials can only provide information on comparability of individual laboratory results with its peers and on assay precision. Using fresh whole blood samples, this study additionally shows that most HbA1c assays are fairly accurate and meet the total allowable error quality target of 5 mmol/mol.

This article offers supplementary material which is provided at the end of the article.

Keywords: accuracy; accuracy-based program; commutability; comparability; external quality assessment schemes; glycated hemoglobin; HbA1c


  • 1.

    World Health Organization. Global report on diabetes. 2016.Google Scholar

  • 2.

    Bunn HF. Nonenzymatic glycosylation of protein: relevance to diabetes. Am J Med 1981;70:325–30.PubMedCrossrefGoogle Scholar

  • 3.

    Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvasular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405–12.CrossrefGoogle Scholar

  • 4.

    The Diabetes Control and Complications Trial Research Group (DCCT). The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968–83.PubMedGoogle Scholar

  • 5.

    Peterson KP, Pavlovich JG, Goldstein D, Little R, England J, Peterson CM, et al. What is hemoglobin A1c? An analysis of glycated hemoglobins by electrospray ionization mass spectrometry. Clin Chem 1998;44:1951–8.PubMedGoogle Scholar

  • 6.

    American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 2017;40 (Suppl. 1):S11–24.PubMedGoogle Scholar

  • 7.

    Gillery P. A history of HbA1c through Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med 2013;51:65–74.PubMedGoogle Scholar

  • 8.

    Miller WG, Jones GR, Horowitz GL, Weykamp C. Proficiency testing/external quality assessment: current challenges and future directions. Clin Chem 2011;57:1670–80.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 9.

    Miller WG. Specimen materials, target values and commutability for external quality assessment (proficiency testing) schemes. Clin Chim Acta 2003;327:25–37.PubMedCrossrefGoogle Scholar

  • 10.

    Miller WG, Myers GL. Commutability still matters. Clin Chem 2013;59:1291–3.Web of ScienceCrossrefPubMedGoogle Scholar

  • 11.

    Vesper HW, Miller WG, Myers GL. Reference materials and commutability. Clin Biochem Rev 2007;28:139–47.PubMedGoogle Scholar

  • 12.

    Delatour V, Liu Q, Vesper HW. Commutability assessment of external quality assessment materials with the difference in bias approach: are acceptance criteria based on medical requirements too strict? Clin Chem 2016;62:1670–1.Web of SciencePubMedGoogle Scholar

  • 13.

    Joint Committee for Guides in Metrology (JCGM). JCGM 200: 2012 International vocabulary of metrology – basic and general concepts and associated terms (VIM) – 3rd edition. 2012.Google Scholar

  • 14.

    Myers GL, Eckfeldt JH, Greenberg N, Levine JB, Miller WG, WiebeDA. CLSI C37-A: National Committee for Clinical Laboratory Standards. Preparation and validation of commutable frozen human serum pools as secondary reference materials for cholesterol measurements procedures; approved guideline. Wayne, PA: NCCLS Document C37-A 1999 NCCLS, 1999.Google Scholar

  • 15.

    Agence nationale de sécurité du médicament. Annales du contrôle national de qualité des analyses de biologie médicale – 15BIO1 – HbA1c. 2015.Google Scholar

  • 16.

    Little Randie R, Roberts William L. A review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol 2009;3:446–51.CrossrefPubMedGoogle Scholar

  • 17.

    INSTAND e.V. – Ringversuchsprogramm [Internet]. [cited 2019 April 29]. Available from: https://www.instand-ev.de/en/eqas/eqa-program.html.

  • 18.

    Kaiser P, Akerboom T, Molnar P, Reinauer H. Modified HPLC-electrospray ionization/mass spectrometry method for HbA1c based on IFCC reference measurement procedure. Clin Chem 2008;54:1018–22.PubMedCrossrefGoogle Scholar

  • 19.

    Jeppsson J, Kobold U, Barr J, Hoelzel W, Hoshino T, Miedema K, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002;35:78–89.Google Scholar

  • 20.

    Hoelzel W, Weykamp C, Jeppsson J-O, Miedema K, Barr JR, Goodall I, et al. IFCC Reference system for measurement of Hemoglobin A1c in human blood and the National Standardization Schemes in the unites States, Japan, and Sweden: a method-comparison study. Clin Chem 2004;50:166–74.CrossrefGoogle Scholar

  • 21.

    Miller WG, Schimmel H, Rej R, Greenberg N, Ceriotti F, Burns C, et al. IFCC working group recommendations for assessing commutability. Part 1: general experimental design. Clin Chem 2018;64:447–54.CrossrefWeb of ScienceGoogle Scholar

  • 22.

    Nilsson G, Budd JR, Greenberg N, Delatour V, Rej R, Panteghini M, et al. IFCC Working Group Recommendations for Assessing Commutability. Part 2: using the difference in bias between a reference material and clinical samples. Clin Chem 2018;64:455–64.Web of ScienceCrossrefGoogle Scholar

  • 23.

    Korzun WJ, Nilsson G, Bachmann LM, Myers GL, Sakurabayashi I, Nakajima K, et al. Difference in bias approach for commutability assessment: application to frozen pools of human serum measured by 8 direct methods for HDL and LDL cholesterol. Clin Chem 2015;61:1107–13.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 24.

    Desirable Biological Variation Database Specifications – Westgard [Internet]. [cited 2019 April 29]. Available from: https://www.westgard.com/biodatabase1.htm.

  • 25.

    Weykamp C, John G, Gillery P, English E, Ji L, Lenters-Westra E, et al. Investigation of 2 models to set and evaluate quality targets for HbA1c: biological variation and sigma-metrics. Clin Chem 2015;61:752–9.PubMedCrossrefGoogle Scholar

  • 26.

    Little RR, Rohlfing CL. Assessing quality from an accuracy-based HbA1c proficiency survey. Clin Chem Lab Med 2016;54:e75–6.PubMedGoogle Scholar

  • 27.

    Kaiser P, Spannagl M, Van Campenhout C, Lenga Y, Siebelder C, Weykamp C. HbA1c: EQA in Germany, Belgium and the Netherlands using fresh whole blood samples with target values assigned with the IFCC reference system. Clin Chem Lab Med 2016;54:1769–75.PubMedGoogle Scholar

  • 28.

    Liu H, Wong L, Yong S, Liu Q, Teo TL, Lee TK, et al. Commutable whole blood reference materials for hemoglobin A1c validated on multiple clinical analyzers. Clin Chem Lab Med 2019;57:648–58.CrossrefPubMedGoogle Scholar

  • 29.

    Weykamp C, John WG, English E, Erasmus RT, Sacks DB, on behalf of the EurA1c Trial Group. EurA1c: the European HbA1c trial to investigate the performance of HbA1c assays in 2166 laboratories across 17 countries and 24 manufacturers by use of the IFCC model for quality targets. Clin Chem 2018;64:1183–92.Web of ScienceCrossrefPubMedGoogle Scholar

  • 30.

    Mosca A, Paleari R, Carobene A, Weykamp C, Ceriotti F. Performance of glycated hemoglobin (HbA1c) methods evaluated with EQAS studies using fresh blood samples: still space for improvements. Clin Chim Acta 2015;451:305–9.PubMedCrossrefGoogle Scholar

About the article

Corresponding author: Dr. Vincent Delatour, Laboratoire National de Métrologie et d’Essais (LNE), 1 rue Gaston Boissier, 75724 Paris Cedex 15, France, Phone: +33 140 434 075

aVincent Delatour and Noémie Clouet-Foraison contributed equally to the writing of this article.

Received: 2019-02-25

Accepted: 2019-04-07

Published Online: 2019-05-14

Published in Print: 2019-09-25

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 57, Issue 10, Pages 1623–1631, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2019-0219.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Supplementary Article Materials

Comments (0)

Please log in or register to comment.
Log in